Trials / Completed
CompletedNCT04358770
Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream
Single Exposure Bioequivalence Study to Evaluate the Vasoconstriction Activity of Topically Applied Cloderm® (Clocortolone Pivalate) 0.1% Cream and Clocortolone Pivalate 0.1% Cream (Taro Pharmaceuticals) in Healthy Male and Female Volunteers With Normal Skin Under Occlusive Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Sun Pharmaceutical Industries, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
To compare pharmacodynamic vasoconstriction response profile of Clocortolone Pivalate 0.1% Cream and Cloderm® (Clocortolone Pivalate) 0.1% Cream in normal skin of healthy male and female adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clocortolone Pivalate | Cream, 0.1% |
Timeline
- Start date
- 2018-03-02
- Primary completion
- 2018-04-27
- Completion
- 2018-05-11
- First posted
- 2020-04-24
- Last updated
- 2020-04-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04358770. Inclusion in this directory is not an endorsement.